Table 1.
Patient, disease, and transplant characteristics
| Total* (N = 1461) | Haplo* (n = 487) | MUD* (n = 974) | P | |
|---|---|---|---|---|
| Age at transplant, y | .018 | |||
| Median (range) | 35 (18-76) | 33 (18-73) | 36 (18-76) | |
| Interquartile range | 25, 49 | 24, 46 | 25, 50 | |
| <30 | 579 (40) | 208 (43) | 371 (38) | .12 |
| 30-39 | 281 (19) | 98 (20) | 183 (19) | |
| 40-54 | 350 (24) | 111 (23) | 239 (25) | |
| ≥55 | 251 (17) | 70 (14) | 181 (19) | |
| Recipient sex | 1.0 | |||
| Male | 909 (62) | 303 (62) | 606 (62) | |
| Female | 552 (38) | 184 (38) | 368 (38) | |
| KPS | .0001 | |||
| 90-100 | 978 (67) | 321 (66) | 657 (67) | |
| ≤80 | 388 (27) | 151 (31) | 237 (24) | |
| NA | 95 (7) | 15 (3) | 80 (8) | |
| Cytogenetic risk | 1.0 | |||
| Poor risk | 489 (33) | 163 (33) | 326 (33) | |
| Not poor | 972 (67) | 324 (67) | 648 (67) | |
| Philadelphia-chromosome status | 1.0 | |||
| Ph+ | 351 (24) | 117 (24) | 234 (24) | |
| Ph− | 1110 (76) | 370 (76) | 740 (76) | |
| Disease stage prior to HCT | 1.0 | |||
| CR1 | 768 (53) | 256 (53) | 512 (53) | |
| CR2+ | 468 (32) | 156 (32) | 312 (32) | |
| Active disease | 225 (15) | 75 (15) | 150 (15) | |
| ALL type | .66 | |||
| B-ALL | 1044 (71) | 345 (71) | 699 (72) | |
| T-ALL | 322 (22) | 113 (23) | 209 (21) | |
| Other | 95 (7) | 29 (6) | 66 (7) | |
| From diagnosis to transplant, mo | .024 | |||
| ≤6 | 398 (27) | 114 (23) | 284 (29) | |
| >6-12 | 510 (35) | 168 (34) | 342 (35) | |
| >12 | 553 (38) | 205 (42) | 348 (36) | |
| HCT Comorbidity Index | <.0001 | |||
| 0 | 147 (10) | 98 (20) | 49 (5) | |
| 1-2 | 92 (6) | 71 (15) | 21 (2) | |
| >2 | 94 (6) | 82 (17) | 12 (1) | |
| NA | 1128 (77) | 236 (48) | 892 (92) | |
| Donor age, y † | <.0001 | |||
| Median (range) | 34 (13-76) | 38 (13-76) | 32 (18-62) | |
| Interquartile range | 26, 45 | 26, 49 | 26, 40 | |
| <30 | 342 (23) | 146 (30) | 196 (20) | <.0001 |
| 30-50 | 443 (30) | 200 (41) | 243 (25) | |
| ≥50 | 127 (9) | 104 (21) | 23 (2) | |
| NA | 549 (38) | 37 (8) | 512 (53) | |
| Donor sex | <.0001 | |||
| Male | 966 (66) | 276 (57) | 690 (71) | |
| Female | 468 (32) | 211 (43) | 257 (26) | |
| NA | 27 (2) | 27 (3) | ||
| Female donor to male recipient | <.0001 | |||
| Yes | 262 (18) | 131 (27) | 131 (13) | |
| No | 1172 (80) | 356 (73) | 816 (84) | |
| NA | 27 (2) | 27 (3) | ||
| Donor/Recipient CMV serostatus | <.0001 | |||
| D−/R− | 318 (22) | 43 (9) | 275 (28) | |
| D−/R+ | 366 (25) | 84 (17) | 282 (29) | |
| D+/R− | 130 (9) | 41 (8) | 89 (9) | |
| D+/R+ | 581 (40) | 303 (62) | 278 (29) | |
| Unknown | 66 (5) | 16 (3) | 50 (5) | |
| Conditioning intensity | 1.0 | |||
| Myeloablative | 1074 (74) | 358 (74) | 716 (74) | |
| Reduced | 387 (26) | 129 (26) | 258 (26) | |
| Stem cell source | <.0001 | |||
| BM | 405 (28) | 237 (49) | 168 (17) | |
| PBMC | 1056 (72) | 250 (51) | 806 (83) | |
| GVHD prophylaxis | ||||
| Sirolimus-based | 23 (2) | 23 (2) | ||
| MTX-based | 664 (45) | 664 (68) | ||
| CellCept-based | 287 (20) | 287 (29) | ||
| PTCy/CellCept/CNI | 487 (33) | 487 (100) | ||
| ATG added | 626 (43) | 0 (0) | 626 (64) | |
| Transplant period | <.0001 | |||
| 2005-2012 | 695 (48) | 86 (18) | 609 (63) | |
| 2013-2018 | 766 (52) | 401 (82) | 365 (37) |
B-ALL, B-cell ALL; CR1, first complete remission; CR2, second complete remission; D, donor; MTX, methotrexate; NA, not applicable; PBMC, peripheral blood mononuclear cell; R, recipient; T-ALL, T-cell ALL.
*
Values expressed as n (%), unless otherwise specified in a row heading.
†
For the “Donor age” section only: Total, N = 912; Haplo, n = 450; MUD, n = 462.